Clinical Trial Update: Study Evaluating MYO-029 in Adult Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating Stamulumab (MYO-029), an experimental myostatin-targeting agent, in adults with Becker muscular dystrophy, facioscapulohu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Becker Muscular Dystrophy
• Facioscapulohumeral Muscular Dystrophy
• Limb Girdle Muscular Dystrophy

Drugs mentioned

• Stamulumab (MYO-029)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED